Table 3.

Currently recruiting EBV CTL trials for PTLD

Study	Intervention	Disease status
NCT03131934 Phase I	Tacrolimus-resistant autologous EBV CTLs	Newly diagnosed or rituximab refractory in SOT patients
NCT02779439 Phase I	HLA-matched third-party donor-derived specific CTLs	Viral infection following allogeneic HCT or SOT
NCT02900976 Phase II	Rituximab + LMP-specific T cells	Newly diagnosed, relapsed, or refractory in SOT patients
NCT03394365 Phase III	Tabelecleucel	(1) SOT after failure of rituximab and rituximab plus chemotherapy; or (2) allogeneic HCT after failure of rituximab
NCT02822495 Expanded access	Tabelecleucel	Relapsed/refractory in SOT and HCT patients

EBV CTLs: Epstein-Barr virus cytotoxic T cell lines; PTLD: post-transplant lymphoproliferative disorder; HCT: hematopoietic cell transplantation; LMP: latent membrane protein.